Table 1.
Overview series on endoscopic treatment and follow-up of submucosal esophageal adenocarcinoma.
| Authors, yearRef | Inclusion period | N | Sm1 (<500 microns) |
Sm2/Sm3 (>500 microns) |
||
|---|---|---|---|---|---|---|
| n | % LNM | n | % LNM | |||
| Manner et al. 201713 | 1996–2010 | 4 | 4 | 0% | ||
| Schölvinck et al. 20169 | 2001–2012 | 33 | 13 LR 10 HR | 0/13 0% 1/10 10% | 10a | 2/10 20% |
| Fotis et al. 201514 | 1994–2013 | 10 | 10 LR | 0/10 0% | ||
| Manner et al. 201512 | 1996–2010 | 43 | 43 37 LR 6 HR | 1/43 2% 1/37 3% 0/6 0% | ||
| Manner et al. 201315 | 1996–2010 | 53a | 53 LR | 1/53 2% | ||
| Alvarez Herrero et al. 201010 | 2000–2008 | 18 | 9 | 0/9 0% | 9 | 0/13 0% |
| Manner et al. 200811 | 1996–2003 | 20a | 20 LR | 0/20 0% | ||
a
Only patients with R0-resection (for neoplasia) were included in this table.
LR: low risk: superficial submucosal invasion <500 microns, good to moderate tumor differentiation, and no lymphovascular invasion; HR: high risk: deep submucosal invasion >500 microns, and/or poor tumor differentiation, and/or lymphovascular invasion; LNM: lymph node metastases; Sm: submucosal.